Publications by authors named "Thomas Sawicki"

Androgen deprivation is the primary therapy for recurrent prostate cancer, and agents targeting the androgen receptor (AR) pathway continue to be developed. Because androgen-deprivation therapy (ADT) has immmunostimulatory effects as well as direct antitumor effects, AR-targeted therapies have been combined with other anticancer therapies, including immunotherapies. Here, we sought to study whether an antigen-specific mechanism of resistance to ADT (overexpression of the AR) may result in enhanced AR-specific T-cell immune recognition, and whether this might be strategically combined with an antitumor vaccine targeting the AR.

View Article and Find Full Text PDF

Background: The androgen receptor (AR) is a key oncogenic driver of prostate cancer, and has been the primary focus of prostate cancer treatment for several decades. We have previously demonstrated that the AR is also an immunological target antigen, recognized in patients with prostate cancer, and targetable by means of vaccines in rodent models with delays in prostate tumor growth. The current study was performed to determine the safety and immunological efficacy of a GMP-grade plasmid DNA vaccine encoding the ligand-binding domain (LBD) of the AR, pTVG-AR.

View Article and Find Full Text PDF

A relatively large, distinct new species of the subterranean amphipod crustacean genus Stygobromus (Amphipoda: Crangonyctidae) measuring 13 mm in length is described from Skipper Spring, a cave spring in the northwestern "panhandle" of Florida, USA. This is the first species of the genus described from the state of Florida where it is described from only 3 females. A fourth much smaller specimen of this species was collected from nearby Miller's Crossing Spring on Holmes Creek.

View Article and Find Full Text PDF